Abcuro

Abcuro is a private, clinical-stage biotech focused on modulating highly cytotoxic T cells, which are key drivers of tissue damage in autoimmune diseases and certain cancers. Its core asset is ulviprubart, an anti-KLRG1 monoclonal antibody, which is in Phase 2/3 development for inclusion body myositis (IBM) and in earlier stages for T-cell leukemias and lymphomas. The company's strategy leverages a novel biological target, KLRG1, to achieve selective immune cell depletion with a potentially improved safety profile. While recent Phase 2/3 data in IBM showed a signal of efficacy but did not meet statistical significance in the overall population, Abcuro is advancing its pipeline in rare diseases with high unmet need.

Monoclonal antibody platform targeting Killer Cell Lectin-Like Receptor G1 (KLRG1) to selectively deplete highly cytotoxic T cells and NK cells.

In IBM, competition includes other immunomodulatory approaches (e.g., anti-CD38, BTK inhibitors) and muscle regeneration therapies, though no drugs are approved. In T-cell malignancies, competition is broader, including chemotherapy, other monoclonal antibodies, and cell therapies. Abcuro's niche is its specific targeting of KLRG1+ cytotoxic cells, a differentiated mechanism.